<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340102</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Navigating the Evolving Landscape of COVID-19: Strategies to Increase Vaccine Confidence and Improve Vaccination Rates in the United States.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1072</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091072</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has had a significant impact on every individual in the United States. The launch of the COVID-19 vaccines is estimated to have averted millions of deaths and reduced over 18 million COVID-19-related hospitalizations. In September 2023, the updated 2023-2024 COVID-19 vaccine, which includes a monovalent component that corresponds to the omicron variant XBB.1.5, reflecting the predominant circulating variant at the time of strain selection, was approved and was recommended for use in all people ≥ 6 months of age. Despite this recommendation, the US uptake of the updated COVID-19 vaccines over the 2023-2024 season has been far from optimal, placing many people at unnecessary risk of severe COVID-19 outcomes. This paper provides an overview of the current state of COVID-19 in 2023-2024 and barriers to vaccine uptake. With the continued evolution of the virus, the potential for more virulent variants, reduced public acceptance of vaccination, and the potential barriers that contributed to low vaccine uptake are explored to provide solutions for improving COVID-19 protection for future seasons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mansi</LastName><ForeName>James A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0001-7650-6778</Identifier><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hensler</LastName><ForeName>Heather R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Moderna, Inc., Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuckson</LastName><ForeName>Reed</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Black Coalition Against COVID, Atlanta, GA 30328, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolynn</LastName><ForeName>Todd</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Kids Plus Pediatrics, Pittsburgh, PA 16046, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shots Heard Round the World, Pittsburgh, PA 16046, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N/A</GrantID><Agency>Moderna, Inc.</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2023–2024 COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccine confidence</Keyword><Keyword MajorTopicYN="N">raising COVID-19 vaccination rates</Keyword></KeywordList><CoiStatement>J.A.M., H.H., and R.D. are employees of and shareholders in Moderna Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340102</ArticleId><ArticleId IdType="pmc">PMC11435598</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091072</ArticleId><ArticleId IdType="pii">vaccines12091072</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC  COVID Data Tracker.  [(accessed on 18 June 2024)]; Available online:  https://covid.cdc.gov/covid-data-tracker.</Citation></Reference><Reference><Citation>CDC  Trends in United States COVID-19 Hospitalizations, Deaths, Emergency Department (ED) Visits, and Test Positivity by Geographic Area.  [(accessed on 15 April 2024)]; Available online:  https://covid.cdc.gov/covid-data-tracker.</Citation></Reference><Reference><Citation>The Commonwealth Fund Two Years of U.S.  COVID-19 Vaccines Have Prevented Millions of Hospitalizations and Deaths.  [(accessed on 15 April 2024)].  Available online:  https://www.commonwealthfund.org/blog/2022/two-years-covid-vaccines-prevented-millions-deaths-hospitalizations.</Citation></Reference><Reference><Citation>CDC  Adult Coverage and Intent.  [(accessed on 18 June 2024)]; Available online:  https://www.cdc.gov/vaccines/imz-managers/coverage/covidvaxview/interactive/adult-coverage-vaccination.html.</Citation></Reference><Reference><Citation>CDC  Child Coverage and Parental Intent for Vaccination.  [(accessed on 15 April 2024)]; Available online:  https://www.cdc.gov/vaccines/imz-managers/coverage/covidvaxview/interactive/children-coverage-vaccination.html.</Citation></Reference><Reference><Citation>CDC  COVID-19 Vaccinations in the United States.  [(accessed on 15 April 2024)]; Available online:  https://covid.cdc.gov/covid-data-tracker.</Citation></Reference><Reference><Citation>Center for Biologics Evaluation and Research Vaccines and Related Biological Products Advisory Committee.  [(accessed on 1 August 2024)]; Available online:  https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee.</Citation></Reference><Reference><Citation>CDC  ACIP Vaccine Recommendations and Schedules.  [(accessed on 1 August 2024)]; Available online:  https://www.cdc.gov/vaccines/acip/recommendations.html.</Citation></Reference><Reference><Citation>Regan J.J. Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥ 6 Months: Recommendations of the Advisory Committee on Immunization Practices—United States, September 2023. MMWR Morb. Mortal. Wkly. Rep. 2023;72:1140–1146. doi: 10.15585/mmwr.mm7242e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7242e1</ArticleId><ArticleId IdType="pmc">PMC10602621</ArticleId><ArticleId IdType="pubmed">37856366</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  COVID-NET—COVID-19-Associated Hospitalization Surveillance Network: A Respiratory Virus Hospitalization Surveillance Network (RESP-NET) Platform.  [(accessed on 6 May 2024)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/covidnetdashboard/de/powerbi/dashboard.html.</Citation></Reference><Reference><Citation>CDC  Laboratory-Confirmed Influenza Hospitalizations.  [(accessed on 6 May 2024)]; Available online:  https://gis.cdc.gov/GRASP/Fluview/FluHospRates.html.</Citation></Reference><Reference><Citation>Zambrano L.D., Newhams M.M., Simeone R.M., Fleming-Dutra K.E., Halasa N., Wu M., Orzel-Lockwood A.O., Kamidani S., Pannaraj P.S., Chiotos K., et al. Characteristics and Clinical Outcomes of Vaccine-Eligible US Children Under-5 Years Hospitalized for Acute COVID-19 in a National Network. Pediatr. Infect. Dis. J. 2024;43:242. doi: 10.1097/INF.0000000000004225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000004225</ArticleId><ArticleId IdType="pmc">PMC11261536</ArticleId><ArticleId IdType="pubmed">38145397</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and without Immunocompromising Conditions—VISION Network, September 2022–April 2023. MMWR Morb. Mortal. Wkly. Rep. 2023;72:579–588. doi: 10.15585/mmwr.mm7221a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7221a3</ArticleId><ArticleId IdType="pmc">PMC10231940</ArticleId><ArticleId IdType="pubmed">37227984</ArticleId></ArticleIdList></Reference><Reference><Citation>Havers F.P. COVID-19–Associated Hospitalizations among Infants, Children and Adults—COVID-NET. January–August 2023.  [(accessed on 6 May 2024)]; Available online:  https://stacks.cdc.gov/view/cdc/132883.</Citation></Reference><Reference><Citation>CDC  Health Policy Data Requests—Percent of U.S. Adults 55 and Over with Chronic Conditions.  [(accessed on 6 May 2024)]; Available online:  https://www.cdc.gov/nchs/health_policy/adult_chronic_conditions.htm.</Citation></Reference><Reference><Citation>CDC  Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals.  [(accessed on 6 May 2024)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html.</Citation></Reference><Reference><Citation>Taylor C.A. COVID-19–Associated Hospitalizations Among U.S. Adults Aged ≥ 65 Years—COVID-NET, 13 States, January–August 2023. MMWR Morb. Mortal. Wkly. Rep. 2023;72:1089–1094. doi: 10.15585/mmwr.mm7240a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7240a3</ArticleId><ArticleId IdType="pmc">PMC10564325</ArticleId><ArticleId IdType="pubmed">37796744</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  Preliminary Flu Burden Estimates, 2022–2023 Season.  [(accessed on 6 May 2024)]; Available online:  https://www.cdc.gov/flu/about/burden/2022-2023.htm.</Citation></Reference><Reference><Citation>CDC  The Changing Threat of COVID-19.  [(accessed on 15 April 2024)]; Available online:  https://www.cdc.gov/ncird/whats-new/changing-threat-covid-19.html.</Citation></Reference><Reference><Citation>Adams M.L., Katz D.L., Grandpre J. Population-Based Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States. Emerg. Infect. Dis. 2020;26:1831. doi: 10.3201/eid2608.200679.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2608.200679</ArticleId><ArticleId IdType="pmc">PMC7392427</ArticleId><ArticleId IdType="pubmed">32324118</ArticleId></ArticleIdList></Reference><Reference><Citation>Kompaniyets L. Underlying Medical Conditions and Severe Illness among 540,667 Adults Hospitalized with COVID-19, March 2020–March 2021. Prev. Chronic Dis. 2021;18:210123. doi: 10.5888/pcd18.210123.</Citation><ArticleIdList><ArticleId IdType="doi">10.5888/pcd18.210123</ArticleId><ArticleId IdType="pmc">PMC8269743</ArticleId><ArticleId IdType="pubmed">34197283</ArticleId></ArticleIdList></Reference><Reference><Citation>Bench2Practice Hospitalizations* by Underlying Medical Condition.  [(accessed on 7 May 2024)].  Available online:  https://atlas.modernatx.com/en-US/bench2practice/Interactive-dashboard.</Citation></Reference><Reference><Citation>Kopel H., Bogdanov A., Winer-Jones J.P., Adams C., Winer I.H., Bonafede M., Nguyen V.H., Mansi J.A. Comparison of COVID-19 and Influenza-Related Outcomes in the United States during Fall–Winter 2022–2023: A Cross-Sectional Retrospective Study. Diseases. 2024;12:16. doi: 10.3390/diseases12010016.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases12010016</ArticleId><ArticleId IdType="pmc">PMC10814040</ArticleId><ArticleId IdType="pubmed">38248367</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  Long COVID—Household Pulse Survey—COVID-19.  [(accessed on 18 June 2024)]; Available online:  https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm.</Citation></Reference><Reference><Citation>United States Census Bureau International Database.  [(accessed on 28 April 2024)]; Available online:  https://www.census.gov/data-tools/demo/idb/#/pop?COUNTRY_YR_ANIM=2021&amp;menu=popViz&amp;COUNTRY_YEAR=2021&amp;TREND_RANGE=1950,2100&amp;TREND_STEP=10&amp;TREND_ADD_YRS=&amp;POP_YEARS=2024&amp;CCODE=US&amp;CCODE_SINGLE=US&amp;popPages=BYAGE&amp;ageGroup=5Y.</Citation></Reference><Reference><Citation>Zheng Y.-B., Zeng N., Yuan K., Tian S.-S., Yang Y.-B., Gao N., Chen X., Zhang A.-Y., Kondratiuk A.L., Shi P.-P., et al. Prevalence and Risk Factor for Long COVID in Children and Adolescents: A Meta-Analysis and Systematic Review. J. Infect. Public Health. 2023;16:660–672. doi: 10.1016/j.jiph.2023.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2023.03.005</ArticleId><ArticleId IdType="pmc">PMC9990879</ArticleId><ArticleId IdType="pubmed">36931142</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistics Canada Government of Canada Experiences of Canadians with Long-Term Symptoms Following COVID-19.  [(accessed on 7 May 2024)].  Available online:  https://www150.statcan.gc.ca/n1/pub/75-006-x/2023001/article/00015-eng.htm.</Citation></Reference><Reference><Citation>Koumpias A.M., Schwartzman D., Fleming O. Long-Haul COVID: Healthcare Utilization and Medical Expenditures 6 Months Post-Diagnosis. BMC Health Serv. Res. 2022;22:1010. doi: 10.1186/s12913-022-08387-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-022-08387-3</ArticleId><ArticleId IdType="pmc">PMC9358916</ArticleId><ArticleId IdType="pubmed">35941617</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael B., Wood G., Sargent B., Ahmad Z.-U.-A., Tharmaratnam K., Dunai C., Egbe F., Martin N., Facer B., Pendered S., et al. Post-COVID Cognitive Deficits at One Year Are Global and Associated with Elevated Brain Injury Markers and Grey Matter Volume Reduction: National Prospective Study. Res. Aquare. 2024 doi: 10.21203/rs.3.rs-3818580/v1. preprint .</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-3818580/v1</ArticleId><ArticleId IdType="pubmed">39312956</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  RESP-NET Interactive Dashboard.  [(accessed on 18 June 2024)]; Available online:  https://www.cdc.gov/surveillance/resp-net/dashboard.html.</Citation></Reference><Reference><Citation>Epic Research Respiratory Illnesses.  [(accessed on 15 April 2024)].  Available online:  https://epicresearch.org/data-tracker/respiratory-illnesses.</Citation></Reference><Reference><Citation>CDC  Influenza Vaccination Coverage, Adults.  [(accessed on 18 June 2024)]; Available online:  https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-adult-coverage.html.</Citation></Reference><Reference><Citation>CDC  Monitoring Variant Proportions.  [(accessed on 15 April 2024)]; Available online:  https://covid.cdc.gov/covid-data-tracker.</Citation></Reference><Reference><Citation>Wang Q., Guo Y., Bowen A., Mellis I.A., Valdez R., Gherasim C., Gordon A., Liu L., Ho D.D. XBB.1.5 Monovalent mRNA Vaccine Booster Elicits Robust Neutralizing Antibodies against Emerging SARS-CoV-2 Variants. bioRxiv. 2023 doi: 10.1101/2023.11.26.568730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.11.26.568730</ArticleId><ArticleId IdType="pmc">PMC10948033</ArticleId><ArticleId IdType="pubmed">38377995</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayed J., Diya O., Lowry F.S., Xu X., Bangad V., Mensa F., Zou J., Xie X., Hu Y., Lu C., et al. Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥ 12 Years Old: A Phase 2/3 Trial. Vaccines. 2024;12:118. doi: 10.3390/vaccines12020118.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12020118</ArticleId><ArticleId IdType="pmc">PMC10893482</ArticleId><ArticleId IdType="pubmed">38400102</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias S., McGhee N., Whatley J.L., Essink B., Brosz A., Tomassini J.E., Girard B., Wu K., Edwards D.K., Nasir A., et al. Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines. medRxiv. 2023 doi: 10.1101/2023.08.22.23293434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.08.22.23293434</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson N.W., Thiesson E.M., Hviid A. Adverse Events after XBB.1.5-Containing COVID-19 mRNA Vaccines. JAMA. 2024;331:1057–1059. doi: 10.1001/jama.2024.1036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2024.1036</ArticleId><ArticleId IdType="pmc">PMC10897819</ArticleId><ArticleId IdType="pubmed">38407875</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCuir J. Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥ 18 Years—VISION and IVY Networks, September 2023–January 2024. MMWR Morb. Mortal. Wkly. Rep. 2024;73:180–188. doi: 10.15585/mmwr.mm7308a5.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7308a5</ArticleId><ArticleId IdType="pmc">PMC10907041</ArticleId><ArticleId IdType="pubmed">38421945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopel H., Araujo A.B., Bogdanov A., Zeng N., Winer I., Winer-Jones J., Lu T., Marks M.A., Bonafede M., Nguyen V.H., et al. Effectiveness of the 2023–2024 Omicron XBB.1.5-Containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19-Related Hospitalizations and Medical Encounters among Adults in the United States: An Interim Analysis. medRxiv. 2024 doi: 10.1101/2024.04.10.24305549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.04.10.24305549</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagiotakopoulos L. Evidence to Recommendations Framework: 2024–2025 COVID-19 Vaccines in Persons ≥6 Months of Age; Proceedings of the ACIP Meeting; Atlanta, GA, USA. 26–28 June 2024.</Citation></Reference><Reference><Citation>Duffy J. COVID-19 vaccine safety surveillance for the 2023–2024 season; Proceedings of the ACIP Meeting; Atlanta, GA, USA. 26–27 June 2024.</Citation></Reference><Reference><Citation>Kusunoki H., Ohkusa M., Iida R., Saito A., Kawahara M., Ekawa K., Kato N., Motone M., Shimizu H. Increase in Antibody Titer and Change over Time Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection after mRNA Vaccination: Consideration of the Significance of Additional Vaccination. Clin. Case Rep. 2024;12:e8953. doi: 10.1002/ccr3.8953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccr3.8953</ArticleId><ArticleId IdType="pmc">PMC11130231</ArticleId><ArticleId IdType="pubmed">38808194</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusunoki H. COVID-19 and the COVID-19 Vaccine in Japan—A Review from a General Physician’s Perspective. Pharmacoepidemiology. 2023;2:188–208. doi: 10.3390/pharma2030017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharma2030017</ArticleId></ArticleIdList></Reference><Reference><Citation>Schöley J., Aburto J.M., Kashnitsky I., Kniffka M.S., Zhang L., Jaadla H., Dowd J.B., Kashyap R. Life Expectancy Changes since COVID-19. Nat. Hum. Behav. 2022;6:1649–1659. doi: 10.1038/s41562-022-01450-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41562-022-01450-3</ArticleId><ArticleId IdType="pmc">PMC9755047</ArticleId><ArticleId IdType="pubmed">36253520</ArticleId></ArticleIdList></Reference><Reference><Citation>Strozza C., Vigezzi S., Callaway J., Aburto J.M. The Impact of COVID-19 on Life Expectancy across Socioeconomic Groups in Denmark. Popul. Health Metr. 2024;22:3. doi: 10.1186/s12963-024-00323-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12963-024-00323-3</ArticleId><ArticleId IdType="pmc">PMC10848407</ArticleId><ArticleId IdType="pubmed">38321440</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet F., Grigoriev P., Sauerberg M., Alliger I., Mühlichen M., Camarda C.-G. Spatial Disparities in the Mortality Burden of the Covid-19 Pandemic across 569 European Regions (2020–2021) Nat. Commun. 2024;15:4246. doi: 10.1038/s41467-024-48689-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-48689-0</ArticleId><ArticleId IdType="pmc">PMC11102496</ArticleId><ArticleId IdType="pubmed">38762653</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajdu T., Krekó J., Tóth C.G. Inequalities in Regional Excess Mortality and Life Expectancy during the COVID-19 Pandemic in Europe. Sci. Rep. 2024;14:3835. doi: 10.1038/s41598-024-54366-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-54366-5</ArticleId><ArticleId IdType="pmc">PMC10869827</ArticleId><ArticleId IdType="pubmed">38360870</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S., Huang R., Sy L.S., Hong V., Glenn S.C., Ryan D.S., Morrissette K., Vazquez-Benitez G., Glanz J.M., Klein N.P., et al. A Safety Study Evaluating Non-COVID-19 Mortality Risk Following COVID-19 Vaccination. Vaccine. 2023;41:844–854. doi: 10.1016/j.vaccine.2022.12.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.12.036</ArticleId><ArticleId IdType="pmc">PMC9763207</ArticleId><ArticleId IdType="pubmed">36564276</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris E. Amid Health Misinformation, Most Trust Physicians for Truth. JAMA. 2023;330:1128. doi: 10.1001/jama.2023.16681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.16681</ArticleId><ArticleId IdType="pubmed">37672301</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagiotakopouluos L. Next Steps for the COVID-19 Vaccine Program; Proceedings of the ACIP Meeting; Atlanta, GA, USA. 28 February 2024.</Citation></Reference><Reference><Citation>CDC  2023–2024 CDC Flu Vaccination Recommendations Adopted.  [(accessed on 28 April 2024)]; Available online:  https://www.cdc.gov/flu/spotlights/2022-2023/flu-vaccination-recommendations-adopted.htm.</Citation></Reference><Reference><Citation>Chatham-Stephens K. An Update on COVID-19 Vaccination Coverage; Proceedings of the ACIP Meeting; Atlanta, GA, USA. 28 February 2024.</Citation></Reference><Reference><Citation>Shen A.K., Browne S., Srivastava T., Kornides M.L., Tan A.S.L. Trusted Messengers and Trusted Messages: The Role for Community-Based Organizations in Promoting COVID-19 and Routine Immunizations. Vaccine. 2023;41:1994–2002. doi: 10.1016/j.vaccine.2023.02.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.02.045</ArticleId><ArticleId IdType="pmc">PMC9932688</ArticleId><ArticleId IdType="pubmed">36803894</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  Adult Immunization Schedule by Age.  [(accessed on 16 April 2024)]; Available online:  https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html.</Citation></Reference><Reference><Citation>CDC  Adult Vaccinations Administered.  [(accessed on 16 April 2024)]; Available online:  https://www.cdc.gov/vaccines/imz-managers/coverage/covidvaxview/interactive/adult-vaccinations-administered.html.</Citation></Reference><Reference><Citation>CDC  Influenza Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults, United States|FluVaxView|Seasonal Influenza (Flu)  [(accessed on 16 April 2024)]; Available online:  https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-administered.html.</Citation></Reference><Reference><Citation>CDC  Interim Clinical Considerations for Use of COVID-19 Vaccines.  [(accessed on 16 April 2024)]; Available online:  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.</Citation></Reference><Reference><Citation>Shanahan E.A., DeLeo R.A., Albright E.A., Li M., Koebele E.A., Taylor K., Crow D.A., Dickinson K.L., Minkowitz H., Birkland T.A., et al. Visual Policy Narrative Messaging Improves COVID-19 Vaccine Uptake. PNAS Nexus. 2023;2:pgad080. doi: 10.1093/pnasnexus/pgad080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pnasnexus/pgad080</ArticleId><ArticleId IdType="pmc">PMC10122412</ArticleId><ArticleId IdType="pubmed">37096197</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyhan B., Reifler J., Richey S., Freed G.L. Effective Messages in Vaccine Promotion: A Randomized Trial. Pediatrics. 2014;133:e835–e842. doi: 10.1542/peds.2013-2365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2013-2365</ArticleId><ArticleId IdType="pubmed">24590751</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer N.T., Chapman G.B., Rothman A.J., Leask J., Kempe A. Increasing Vaccination: Putting Psychological Science into Action. Psychol. Sci. Public Interest. 2017;18:149–207. doi: 10.1177/1529100618760521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1529100618760521</ArticleId><ArticleId IdType="pubmed">29611455</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer N.T., Hall M.E., Malo T.L., Gilkey M.B., Quinn B., Lathren C. Announcements Versus Conversations to Improve HPV Vaccination Coverage: A Randomized Trial. Pediatrics. 2016;139:e20161764. doi: 10.1542/peds.2016-1764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2016-1764</ArticleId><ArticleId IdType="pmc">PMC5192091</ArticleId><ArticleId IdType="pubmed">27940512</ArticleId></ArticleIdList></Reference><Reference><Citation>Opel D.J., Heritage J., Taylor J.A., Mangione-Smith R., Salas H.S., DeVere V., Zhou C., Robinson J.D. The Architecture of Provider-Parent Vaccine Discussions at Health Supervision Visits. Pediatrics. 2013;132:1037–1046. doi: 10.1542/peds.2013-2037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2013-2037</ArticleId><ArticleId IdType="pmc">PMC3838535</ArticleId><ArticleId IdType="pubmed">24190677</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty C.T., Crues L. How to Talk to Reluctant Patients About the Flu Shot. Fam. Pract. Manag. 2017;24:6–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28925620</ArticleId></ArticleIdList></Reference><Reference><Citation>Infodemiology Infodemiology Training for Public Health.  [(accessed on 28 May 2024)].  Available online:  https://training.infodemiology.com/publichealth.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>